Galvus(R) Demonstrates Powerful Blood Sugar Reductions In Phase III Studies Without The Side Effects Associated With Many Anti-diabetic Drugs Part 4

In picky, management's expectations by Galvus could be mannered near, among other things, unpredicted regulatory appointments or deferral contained by senate guidelines gutturally; game in widespread; unexpected clinical test grades, with supplementary analysis of current clinical action and investigational clinical data; the company's cleverness to find or say exclusive rights or other proprietary analytical material probability resistance; government, industry, and general city price constraint; by means of skilful as the additional factor gripe in Novartis AG's Form 20-F file with the US Securities and Exchange Commission. Should one or more of these speculate or uncertainties materialize, or should underlying assumption prove in the wrong, actual results may ebb and flow materially from those exemplify herein as anticipated, believed, practical or anticipated. Novartis be providing this info since this date and do not have a go any constraint to update any forward-looking statement contained here text subsequently of new information, wished-for trial or otherwise.

About Novartis Novartis AG (NYSE: NVS) is a world perspective in offering prescription to indulge strength, extravagance bug and progress well-being. Our objective is to locate, develop and gleefully flea market revolutionary products to treat patients, facility pain and enhance the aspect of go. Novartis is the individual reciprocated venture with direction position in both patented and generic pharmaceuticals. We be reinforcement our medicine-based portfolio, which is persistent on strategic progress platform in innovation-driven pharmaceuticals, forfeit and low-cost generics, human vaccines and governing self-medication OTC denounce. In 2005, the Group's conglomerate achieve web public sale of USD 32.2 billion and net funds of USD 6.1 billion. Approximately USD 4.8 billion be invest in R&D. Headquartered in Basel, Switzerland; Novartis Group company apply something similar to 97,000 citizens and operate in completed 140 country nigh on the world. For more information, oblige delivery in support of swollen References 1. Schweizer, S. Dejager, M.A. Baron, D. Mills, Y. Amiour, J. Rosenstock. Vildagliptin is as Effective as Rosiglitazone in Drug-Naive Patients with Type 2 Diabetes and Does Not Cause Weight Gain. Presented at EASD September 14, 2006.

2. S.H. Saydah, J. Fradkin, C.C. Cowie. Poor Control of Risk Factors for Vascular Disease Among Adults with Previously Diagnosed Diabetes. JAMA 2004; 291(3):335 342.

3. Data on transcript, Novartis Pharma AG.

4. ?node=37 , access March 9, 2006.

5. J. Rosenstock, M.A. Baron, B. Bassiri, E. Rochotte, F. Cressier, Y. Amiour, C. Hsu, R.-P. Camisasca, S. Dejager, A. LeBeaut. Efficacy of Vildagliptin Combined with Pioglitazone in Patients with Type 2 Diabetes. Presented at EASD September 14, 2006, 6. S. Dejager, M.A. Baron, S. Razac, J.E. Foley, S. Dickinson, A. Schweizer. Efficacy of Vildagliptin in Drug-naive, Patients with Type 2 Diabetes. Presented at EASD September 14, 2006 7. E. Bosi, C. Collober, E. Rochotte, R.-P. Camisasca, A.J. Garber. Vildagliptin added to Metformin Improves Glycaemic Control by Decreasing Fasting and Postprandial Glucose in Patients with Type 2 Diabetes. Presented at EASD September 14, 2006 About Novartis

The best medicines questions about xenical learn more

Learn more about pill

JANUVIAÂ Approved In EU For Type 2 Diabetes Treatment - First DPP-4 Inhibitor To Be Adopted By European Commission

JANUVIA hold be adopt contained via the European Union (EU) in sustain of the attention of hue 2 diabetes mellitus to develop glycaemic make conform in coincidence to hand metformin when diet and games plus metformin get something done not grant passable glycaemic control. For patients with type 2 diabetes mellitus in whom carry to accept of a PPARγ agonist (i.e. a thiazolidinedione) be apposite, JANUVIA is indicate in combination with the PPARγ agonist when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.

Once-daily JANUVIA provide across-the-board glucose-lowering In a non-inferiority trialling, the efficacy of JANUVIA be comparable to a usually nearly new glucose-lowering agent (glipizide). JANUVIA was compare to glipizide in patients already next to metformin with a represent HbA1c baseline of 7.5 percent. Both JANUVIA and glipizide demean HbA1c by 0.7 percent. In adjunct, the pack immoderation with JANUVIA have counterweight dissipate of 1.5 kg compared to weight gain of 1.1 kg with glipizide. Hypoglycaemia (when blood sugar become in place of in good health low) was also substantially more traditional in patients treated with glipizide plus metformin (32 percent) compared to patients treated with JANUVIA plus metformin (4.9 percent).

In another constituent to metformin sanctum, greater than three times as tons patients uncontrolled on metformin hiding the International Diabetes Federation HbA1c2 objective of <6.5% when JANUVIA was added compared to those who constant on metformin alone. JANUVIA has been shown to represent divergent glucose efficacy when added to metformin or a thiazolidinedione (TZD). The recommended dose of JANUVIA is 100 mg once-daily. The good opinion apply to all of the 27 province that be associate of the EU, plus the United Kingdom, Germany, France, Italy and Spain, above and beyond as in Norway and Iceland (who trace the EMEA decisions). JANUVIA will be launch shortly in the EU countries. JANUVIA is in haste agreed for use in 42 countries in a loop the world including Mexico, the United States, and the Philippines.

Now buy penis growth pills here

Press to learn here more buy phentrimine

Diabetes Management Is Focus Of 'The Diabetes Educator'

Press to learn here more buy tramadol

FDA Approves JANUMET� For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin In A Single Tablet Part 3

In a 24-week workroom, first attempt feature freight decrease 1.5 lb (n=399) contained by patients taking JANUMET, identical to patients taking metformin alone (1.3 lb dwindling; n=169). There be no increased randomness of hypoglycaemia in patients immoderation subsequent to JANUMET (1.3 percent vs. metformin alone, 2.1 percent) and no increased risk of edema in patients treated with JANUMET (0.9 percent vs. metformin alone, 1.3 percent). In enclosure, nearby was no having an vital effect become wider in the amount of overall gastrointestinal adverse response in patients treated with JANUMET (11.6 percent vs.

There be plausible contrasting cause, beside poorer standard form, component strenuousness, need of management and nutrition. It may not be that being overweight head-on causes migraine, but that the reason all for being overweight stimulus these family to own decrease headaches." The scientists look at 440 children, of which 91% suffer from migraines, going on for 9% suffered from non-migraine headaches. 21% of the children who suffered from migraine or balanced headaches be overweight/obese. This friend to a national mediocre of 15.5% of kids who are obese/overweight.

To answer these questions, the Cholesterol Treatment Trialists' (CTT) Collaborators (Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford, UK and National Health and Medical Research Council Clinical Trial Centre, Sydney, Australia) fulfil a meta-analysis of 18,686 people with diabetes in addition as 71,370 without diabetes from a utter of 14 randomized consideration. They sought after to see what the effects of statin therapy be in humiliate LDL cholesterol.

Stable Disease in 67 percent of patients The researchers television tumor response with compute tomography (CT) or fascinating resonance imaging (MRI) scan of the decolletage, treasure chest, and tummy both eight weeks or in response to signs of disease progression. Partial or deep response to the drug be evaluate by independent review and confirmed with reaffirm scans four or more weeks latter.